Regulus Therapeutics Inc

Regulus Therapeutics — Investor Presentation (December 2020)

43 slides from Regulus Therapeutics's investor presentation, Dec 1, 2020

  1. Slide 1: Corporate Presentation – December 2020

    Corporate Presentation – December 2020 Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to underta

  3. Slide 3: Regulus Recent Highlights

    Initiated Phase 1b study of RGLS4326 in patients with ADPKD Data from first cohort anticipated in Q1 2021 Plans to engage FDA on remaining clinical hold requirements Successfully restructured Sanofi and Oxford agreements Received $10m from Sanofi for achievement of milestones and certain materials R

  4. Slide 4: Regulus Therapeutics Overview

    Regulus Therapeutics Overview Leading microRNA company focused on translating novel technology into innovative therapeutics Pioneering microRNA therapeutics targeting genetic kidney disease in the clinic with RGLS4326 in ADPKD and RG-012 in Alport Syndrome Advancing broader pipeline targeting novel

  5. Slide 5: Regulus Development Pipeline

    Preclinical Phase 1 Phase 2 Phase 3 Commercial RG-012: Alport Syndrome RGLS4326 : ADPKD Undisclosed : Hepatitis B RGLS5579 : Glioblastoma anti-miR-132 : NASH Undisclosed : CAR-T, NK Regulus Development Pipeline Renal Infectious Disease Oncology Metabolic Disease Cell Therapy

  6. Slide 6: RG-012, Anti-miR-21 for the Treatment of Alport Syndrome

    RG-012, Anti-miR-21 for the Treatment of Alport Syndrome Sanofi Managed Phase 2 Currently Enrolling Patients Chronic treatment with RG-012 is well tolerated (Q2W for one year) Clinical demonstration of desired exposure and modulation of microRNA target in kidney Sanofi has assumed development respon

  7. Slide 7: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Autosomal Dominant Polycystic Kidney Disease (ADPKD) Orphan disease due to mutations in either PKD1 or PKD2 genes, causing proliferation and fluid-filled cysts in kidneys 50% 85% 160,000 patients with PKD1 mutation diagnosed individuals in U.S. patients develop ESRD by age 60 Patient population Heal

  8. Slide 8: Genetic Renal Disease with High Unmet Need

    Genetic Renal Disease with High Unmet Need Fourth leading cause of kidney failure and more than 50 percent of people with ADPKD develop kidney failure by age 50 Renal manifestation includes bilateral renal enlargement containing multiple fluid-filled cysts, renal pain and renal insufficiency Extrare

  9. Slide 9: Burgeoning Market with Few Competitors

    Burgeoning Market with Few Competitors Jynarque® (tolvaptan, vasopressin V2 antagonist) – only approved therapy in U.S. FDA approval in April 2018 Boxed warning due to potentially fatal liver injury & failure requiring transplant REMS program with restricted distribution and ongoing liver monitoring

  10. Slide 10: RGLS4326 Preliminary Target Product Profile

    RGLS4326 Preliminary Target Product Profile RGLS4326 designed to antagonize miR-17, an overexpressed microRNA that regulates PKD1 and PKD2 expression Disease modifying agent to slow progression of cyst development and renal impairment in ADPKD Aim to demonstrate clinically significant reduction in h

  11. Slide 11: RGLS4326 Mechanism of Action

    Lee et al., (2019)10:4148 Nat. Comm. In ADPKD, mutations in PKD1 and PKD2 genes disrupt normal functions of their encoded proteins polycystin-1 (PC1) and polycystin-2 (PC2) in renal tubular epithelium, causing proliferation and fluid filled cysts in kidneys RGLS4326 binds miR-17 de-repressing miR-17

  12. Slide 12: miR-17 is Upregulated in Mouse Kidney Cysts and Human ADPKD Cyst Cells

    miR-17 is Upregulated in Mouse Kidney Cysts and Human ADPKD Cyst Cells Human Kidney Samples In-situ hybridization Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 Normal Human Kidney ADPKD Kidney miR-17 probe miR-17 probe Control probe Control probe Mouse Kidney Samples qPCR analysis Normal Kidney

  13. Slide 13: miR-17 Directly Binds PKD1 and PKD2 Genes

    miR-17 Directly Binds PKD1 and PKD2 Genes – the Mutated Genes in ADPKD 3’UTRs of PKD1 and PKD2 contain conserved miR-17 binding sequences miR-17 mimic represses Pkd1 and Pkd2 in mouse collecting duct (IMCD3) cells PNAS 2013 June;110(26): 10765-10770 WT: wildtype 3’UTR MT: mutated 3’UTR PKD1: 3’UTR c

  14. Slide 14: Targeting miR17 Shows Derepression of Pkd1 and Pkd2 Gene Expression

    Age: D1 D10 D11 D12 D19 D28 (18d treatment) Targeting miR17 Shows Derepression of Pkd1 and Pkd2 Gene Expression in Pkd2-KO Mice Inject Lee et al., (2019)10:4148 Nat. Comm.

  15. Slide 15: Targeting miR17 with RGLS4326 Increases Polycystin Levels in Human ADPKD Cyst Cells

    Targeting miR17 with RGLS4326 Increases Polycystin Levels in Human ADPKD Cyst Cells in vitro 3.7 FC 1.9 FC **p<0.01 *p<0.05 All versus Mock PC1 Expression PC2 Expression * ** Lee et al., (2019)10:4148 Nat. Comm.

  16. Slide 16: Polycystin Levels are Significantly Lower in ADPKD Patients

    Polycystin Levels are Significantly Lower in ADPKD Patients and Correlate with Disease Severity Preliminary Data; In collaboration with Dr Chris Ward at KUMC Hogan et al., JASN 26: 1661-1670, 2015 PC1 levels from patient samples significantly lower than normal levels MS/MS data Low PC1 High PC1 Low

  17. Slide 17: Knockdown of miR-17~92 Cluster Attenuates Disease in Two ADPKD Mouse Models

    Kidney-specific Knockdown of miR-17~92 Cluster Attenuates Disease in Two ADPKD Mouse Models Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 b, f: Serum Creatinine c, g: % Proliferation based on number of pHH3+ proliferating cyst epithelial cells

  18. Slide 18: Knockdown of miR-17~92 Cluster Attenuates Disease in Pkd1F/RC Mouse Model

    Kidney-specific Knockdown of miR-17~92 Cluster Attenuates Disease in ADPKD Mouse Model (Pkd1F/RC) Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 MRI Imaging c: Serum Creatinine d: % Proliferation based on number of pHH3+ proliferating cyst epithelial cells

  19. Slide 19: Slowing of Disease Progression by Anti-miR-17 Tool Oligo in Pkd2-KO Mice

    Slowing of Disease Progression by an Anti-miR-17 Tool Oligo in Pkd2-KO Mouse Model Age: D1 H&E (D28) H&E (D28) D10 D11 D12 D19 D28 (18d treatment) Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 (D28) (D28) (D28) (D28) WT-C57BL6 #: % Proliferation based on number of pHH3+ proliferating cyst epithe

  20. Slide 20: RGLS4326 Preferentially Distributes to the Kidney and Localizes to Renal Cysts

    RGLS4326 Preferentially Distributes to the Kidney and Localizes to Renal Cysts Tissue distribution profile of RGLS4326 based on quantitative whole-body autoradiography in male CD1 mice after a single SC dose of 30mg/kg Representative immunofluorescence image of kidney samples of Pkd2-KO mice after f

  21. Slide 21: RGLS4326 Shows Favorable PK/PD Profiles After a Single SC Dose

    RGLS4326 Shows Favorable PK/PD Profiles After a Single Subcutaneous (SC) Dose of 30 mg/kg Lee et al. (2018) ASN-Kidney Week; Poster Presentation (A) RGLS4326 was rapidly absorbed into and cleared from plasma. RGLS4326 distributed primarily to kidney, with kidney-to-liver ratio of >10-fold by Cmax. (

  22. Slide 22: RGLS4326 is Efficacious in the Pcy/DBA Mouse Model

    15w (sacrifice) RGLS4326 is Efficacious in the Pcy/DBA Mouse Model Lee et al. (2018) ASN-Kidney Week; Poster Presentation Age: 6w 14w Pcy/DBA: Tolvaptan (Chow; ad libitum) RGLS4326 (QW) Randomized statistically-powered study performed at Regulus; Results confirmed by a blinded study with same study

  23. Slide 23: RGLS4326 Reduces Rate of bwTKV Increase in the Pcy/DBA Mouse Model

    RGLS4326 Reduces Rate of bwTKV Increase in the Pcy/DBA Mouse Model of PKD Changes in body-weight adjusted total kidney volume (bwTKV) from baseline at week 8, 11 and 14 was significantly reduced after RGLS4326 treatment by 25%, 37% and 50%, respectively (p<0.05 for all). Stabilization Reduction Redu

  24. Slide 24: RGLS4326 Clinical Status – Phase 1b MOA Study Underway

    SAD complete up to top dose of 6 mg/kg in healthy volunteers MAD complete up to top dose of 1 mg/kg (Q2W x 4) SAD/MAD results indicate administration of RGLS4326 was well-tolerated with no SAEs reported and dose proportional PK Phase 1b MOA study underway – first patient dosed in Cohort 1 Open label

  25. Slide 25: RGLS4326 Program Summary

    RGLS4326 Program Summary FDA Lifted Partial Clinical Hold in December 2019 enabling company to resume MAD study Completion of chronic toxicity studies and satisfactory safety margins enabled reinitiation of Phase 1 studies in healthy volunteers and patients with ADPKD Healthy volunteer portion (SAD/

  26. Slide 26: Hepatitis B

    Hepatitis B Hepatitis B is a liver infection caused by the Hepatitis B virus that can lead to serious health issues, like cirrhosis and liver cancer <10% 50% people infected globally liver cancer cases caused by HBV cure rate for standard of care Patient population Current treatments new mechanisms

  27. Slide 27: Targeting Novel microRNA Shows Sub-Nanomolar Potency and >95% Reduction in HBsAg in vitro

    Targeting Novel microRNA Shows Sub-Nanomolar Potency and >95% Reduction in HBsAg in vitro

  28. Slide 28: Potent Anti-Viral Activity Demonstrated in Primary Human Hepatocyte Assay

    Potent Anti-Viral Activity Also Demonstrated in vitro in a Primary Human Hepatocyte Assay Day -1: Seed PHH, add oligo Day 0: Add virus Day 1: Remove virus, add GS-5801 (10mm) Day 5, 8, 11, and 14: Measure virus in supernatant (HBV DNA) Day 17: Measure cell viability Day 5, 8 and 11: GS-5801 replenis

  29. Slide 29: Pilot in-vivo Studies Demonstrate POC of Oligo Impact on HBV Replication

    Pilot in-vivo Studies Demonstrate POC of Oligo Impact on HBV Replication AAV-HBV infected mice were dosed with active oligo (30 mg/kg SC q.4.d. x6) +/- ETV (0.1 mg/kg PO q.d. x14). Oligo treatment suppressed viral titer (serum DNA) and extended the activity of ETV treatment. This oligo also targeted

  30. Slide 30: Dose Dependent Reduction in Viral Load and Surface Antigen in-vivo

    Dose Dependent Reduction in Viral Load and Surface Antigen Demonstrated in-vivo Mice with established AAV-HBV infection were dosed 6 times with 30 mg/kg or 60 mg/kg of active oligo S.C. every 4 days.

  31. Slide 31: SAR Campaign Shows Optimized Oligo has Enhanced Activity

    SAR Campaign Shows Optimized Oligo has Enhanced Activity Mice with established AAV-HBV infection were dosed 6 times with 30 mg/kg of oligo S.C. every 4 days. µL

  32. Slide 32: Pre-treatment with Oligo Enhances Anti-Viral Effect of IFNa

    Pre-treatment with Oligo Enhances the Anti-Viral Effect of IFNa in the AAV-HBV Model Mice with established AAV-HBV infection were dosed 6 times with 30 mg/kg of oligo S.C. every 4 days. After 4 doses with the oligo the mice were treated with a sub-efficacious dose of mouse IFNa (400 IU/g, TIW, I.P.)

  33. Slide 33: Oligo Treatment Blocks HBcAg Expression in the Liver

    Oligo Treatment Blocks HBcAg Expression in the Liver Control group Oligo (30 mg/kg x6) Oligo (60 mg/kg x6) Mice with established AAV-HBV infection were dosed 6 times with 30-60 mg/kg of oligo S.C. every 4 days. On day 35 HBcAg was measured by IHC µL

  34. Slide 34: Oligo Treatment Reduces cccDNA Levels

    Oligo Treatment Reduces cccDNA Levels Key: A = AAV-HBV B = Marker C = HepDES19 control A B C Reference Data Raw Data Normalized Data Mice with established AAV-HBV infection were dosed 6 times with oligo S.C. every 4 days, or ETV 0.1 mg/kg PO QD x14. Livers were taken after 75 days and the cccDNA-lik

  35. Slide 35: Targeting microRNA - A Novel Approach Toward a Functional Cure

    Targeting microRNA - A Novel Approach Toward a Functional Cure Combinations of currently approved drugs and those in development will be required to attain a high rate of functional cure - new approaches are required to make this possible Targeting microRNA-host factor pathways is a unique approach

  36. Slide 36: miRNA Modulation of Cell Therapy

    miRNA Modulation of Cell Therapy Rapid maturation of Cell Therapy industry capabilities, with three commercially available autologous treatments for hematological cancers Global cancer cell therapy pipeline of 1,483 active programs* with majority preclinical stage 858 CAR-T programs, 90 NK programs

  37. Slide 37: Ex Vivo Modulation of Cell Therapies: An Overview

    Ex Vivo Modulation of Cell Therapies: An Overview Antibodies Extracellular targets Narrow range of targets Only active during culture Simple Small Molecule Intracellular targets Single pathway modulation Very short half-life Only active during culture Simple microRNA Intracellular targets Multiple p

  38. Slide 38: Targeting microRNA May Improve Several Issues of Cell-Based Therapies

    Targeting microRNA May Improve Several Issues of Cell-Based Therapies Potential Benefits Improved persistence Improved fitness Resistance to exhaustion Optimized phenotype

  39. Slide 39: Preliminary Data Modulating T cells by targeting different microRNA

    Preliminary Data Modulating T cells by targeting different microRNA HER2 CAR: 4D5 clone, 2nd gen 41BB. Construct purchased from ProMab Bio. GD2 CAR: 14G2a clone, 2nd gen CD28. Construct designed on Long et al. 2015. Selected for poor in vitro characteristics. Enhance T cell Proliferation Prevent T c

  40. Slide 40: Modulating microRNA Can Enhance Cytokine Production and Target Cell Killing

    Modulating microRNA Can Enhance Cytokine Production and Target Cell Killing Cytokine production by Her2 CAR-T cells treated with microRNA inhibitor A was assessed after 24h co-culture with HER2+ HCC38 cells. Proprietary oligo found to enhance the production of several pro-inflammatory cytokines cons

  41. Slide 41: Summary: microRNA for Cell Therapy

    Summary: microRNA for Cell Therapy Targeting microRNA holds the potential to modulate multiple cell types (eg, CAR, NK, iPSC, and cardiomyocytes) across several therapeutic applications Early demonstration that targeting microRNA can control T-cell phenotype and performance Expansion rates and resis

  42. Slide 42: Potential Upcoming Catalysts

    Potential Upcoming Catalysts Catalyst Potential Timing Results from the first cohort of RGLS4326 Phase 1b Late Q1 2021 FDA engagement for feedback on approach to addressing remaining hold requirements Mid 2021 Topline data for remaining RGLS4326 Phase 1b cohorts 2H 2021 Potential resolution of remai

  43. Slide 43: Corporate Presentation – December 2020

    Corporate Presentation – December 2020

Regulus Therapeutics — Investor Presentation (December 2020) on 6ix